<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HFA02D98EB70F4CB6AAD57F7D1614D74F" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5062 IH: Advancing Access to Precision Medicine Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-02-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5062</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180215">February 15, 2018</action-date><action-desc><sponsor name-id="S001193">Mr. Swalwell of California</sponsor> (for himself, <cosponsor name-id="S000364">Mr. Shimkus</cosponsor>, <cosponsor name-id="P000608">Mr. Peters</cosponsor>, <cosponsor name-id="P000594">Mr. Paulsen</cosponsor>, and <cosponsor name-id="V000130">Mr. Vargas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To provide for a study by the National Academy of Medicine on the use of genetic and genomic
			 testing to improve health care, and for other purposes.</official-title></form>
	<legis-body id="HD5ED7BDB2D70467DB930757D98323760" style="OLC">
 <section id="HC66561C31E9A41F7963E69C15F4E549A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Advancing Access to Precision Medicine Act</short-title></quote>.</text> </section><section id="H0CD0B9402CD34BCDA2D9752FBB8A53E5"><enum>2.</enum><header>National Academy of Medicine study</header> <subsection id="HB1068E7E89204AE1B7FCDFC18F3D20B6"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 60 days after the date of the enactment of this Act, the Secretary <italic></italic>of Health and Human Services shall enter into an arrangement with the National Academy of Medicine under which the Academy agrees to study—</text>
 <paragraph id="H63D5AF4BB49E4631B92554E735380CC1"><enum>(1)</enum><text display-inline="yes-display-inline">how genetic and genomic testing may improve preventative care and precision medicine;</text> </paragraph><paragraph id="HAFF1B616415D4D39A3D5511061CD4991"><enum>(2)</enum><text display-inline="yes-display-inline">how genetic and genomic testing may reduce health disparities;</text>
 </paragraph><paragraph id="H3C65F67C326446E9AE70B8F1775BDA67"><enum>(3)</enum><text display-inline="yes-display-inline">how the Federal Government may help to reduce barriers to genetic and genomic testing, including—</text> <subparagraph id="H6772359048DB4E1AA5D6B9C4B1DD009D"><enum>(A)</enum><text>encouraging the expansion of health insurance coverage of genetic and genomic testing, including diagnostic, predictive, and presymptomatic testing, and whole genome sequencing;</text>
 </subparagraph><subparagraph id="HA32D0EFE47ED43F6BA7C3C302AFFD67E"><enum>(B)</enum><text>supporting the collection of evidence for the clinical utility and appropriate use of genetic and genomic tests; and</text>
 </subparagraph><subparagraph id="H272463CABE614931A062855E32431B6B"><enum>(C)</enum><text display-inline="yes-display-inline">improving access to genetic counselors, pathologists, and other relevant professions, including strengthening related workforce education and training efforts;</text>
					</subparagraph></paragraph><paragraph id="H2DBFB92AFB8B426B84539F439B138A92"><enum>(4)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="HB5669F19D1F34EE390697D4572C94085"><enum>(A)</enum><text>the extent to which coverage provisions in the Medicare and Medicaid programs under titles XVIII and XIX of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395</external-xref> et seq., 1396 et seq.) may restrain the use of genetic and genomic testing that may improve clinical outcomes for beneficiaries; and</text>
 </subparagraph><subparagraph id="HA62B0D8B6966469CA198DBC1A5695B6F" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">how the Centers for Medicare &amp; Medicaid Services may make coverage determinations that better suit a precision medicine approach to treatment; and</text>
 </subparagraph></paragraph><paragraph id="H75D7329FB7E34C3DB7C99CF99EEB9713"><enum>(5)</enum><text>how genetic and genomic testing may improve health outcomes for all populations in the United States, including—</text>
 <subparagraph id="HE21DD19C29774CD9B87A8AA712B7D8D4"><enum>(A)</enum><text>individuals with a rare disease, including—</text> <clause id="HA0CE40A056A94D879E1EC8D53010EDB1"><enum>(i)</enum><text>a metabolic disease;</text>
 </clause><clause id="HA77A6BDF7E3E4DC0B9D39CFBE827A849"><enum>(ii)</enum><text>a hereditary cancer syndrome; and</text> </clause><clause id="H7926E22D4B5F4AB1AF0A0895E4E7F9D4"><enum>(iii)</enum><text>a neurologic disease with known treatments; and</text>
 </clause></subparagraph><subparagraph id="H28C8A69A64814CD094B3E499A2BFC8FA"><enum>(B)</enum><text>special populations, including—</text> <clause id="H434AB1CB007640A6B42AA6C0FCEE8DE2"><enum>(i)</enum><text>infants and children;</text>
 </clause><clause id="H3AABF1DBF9A044E2BE1C39D2F642E403"><enum>(ii)</enum><text>critically ill (non-infectious and non-trauma) patients;</text> </clause><clause id="HC3F26E9E249147AB857970C7C259502A"><enum>(iii)</enum><text>transplant patients;</text>
 </clause><clause id="HDA34098E6FAD45649472052229A62897"><enum>(iv)</enum><text>individuals with cardiac disease; and</text> </clause><clause id="H9733B63BAB7F4AF2806A202BCD4CB981"><enum>(v)</enum><text>individuals with, or who have a family history of, a birth defect or developmental disability.</text>
						</clause></subparagraph></paragraph></subsection><subsection id="H4DA2F5635EEE4DE39C191EAE0125B457"><enum>(b)</enum><header>Report</header>
 <paragraph id="H63DF1584CA294A5BB3409F495AE422FE"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The arrangement under subsection (a) shall provide for the National Academy of Medicine to submit, not later than 3 years after the date of enactment of this Act, a report on the results of the study under subsection (a) to—</text>
 <subparagraph id="H69CEC5C588A2492DA0DBB5A4F9507F8E"><enum>(A)</enum><text>the Secretary of Health and Human Services;</text> </subparagraph><subparagraph id="H7D591DE71AD84A8A96E479736AD88EDE"><enum>(B)</enum><text>the Committee on Ways and Means and the Committee on Energy and Commerce of the House of Representatives; and</text>
 </subparagraph><subparagraph id="H338E60C3B4774B0ABE3899AB06B8E056"><enum>(C)</enum><text>the Committee on Finance and the Committee on Health, Education, Labor, and Pensions of the Senate.</text> </subparagraph></paragraph><paragraph id="H475DCBCF514148EC9007095A3F47AC8A"><enum>(2)</enum><header>Consultation</header><text display-inline="yes-display-inline">The arrangement under subsection (a) shall provide for the National Academy of Medicine, in developing the report required by paragraph (1), to consult with physicians, other health professionals, health educators, health professional organizations, relevant companies, patients, patient organizations, the Health Resources and Services Administration, the National Cancer Institute, the National Institutes of Health, the Agency for Healthcare Research and Quality, and the Centers for Medicare &amp; Medicaid Services.</text>
 </paragraph></subsection></section><section id="H685A65967FB74C5D89CF148CE6F225FF"><enum>3.</enum><header>State option to provide whole genome sequencing clinical services for certain children</header><text display-inline="no-display-inline">Title XIX of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396</external-xref> et seq.) is amended by inserting after section 1943 the following new section:</text>
			<quoted-block display-inline="no-display-inline" id="HF3FC2382E9B645EAA1B70F53884A9432" style="OLC">
				<section id="H24FECFC566774E49AF20E2A7B9740269"><enum>1944.</enum><header>State option to provide whole genome sequencing clinical services for certain children</header>
 <subsection id="H0E7227BDA512453BB6189B946F0A0D17"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Notwithstanding section 1902(a)(1) (relating to statewideness), section 1902(a)(10)(B) (relating to comparability), and any other provision of this title for which the Secretary determines it is necessary to waive in order to implement this section, beginning January 1, 2019, a State, at its option as a State plan amendment, may provide for medical assistance under this title to an eligible individual for purposes of providing the individual with whole genome sequencing clinical services.</text>
					</subsection><subsection id="H2646F209CAEC4C9D8798B313D5619359"><enum>(b)</enum><header>Payments</header>
 <paragraph id="H1AB9F1CB57FC4FC2B061DD2803AAA770"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">A State shall provide a health care provider (as defined by the State) with payments for the provision of whole genome sequencing clinical services to any eligible individual. Payments made to a health care provider for such services shall be treated as medical assistance for purposes of section 1903(a), except that, during the first 8 fiscal year quarters that the State plan amendment is in effect, the Federal medical assistance percentage applicable to such payments shall be equal to 75 percent.</text>
 </paragraph><paragraph id="HD167751C42E049CEAEDBBB4BE2D8735D"><enum>(2)</enum><header>Methodology</header><text display-inline="yes-display-inline">The State shall specify in the State plan amendment the methodology the State will use for determining payment for the provision of whole genome sequencing clinical services. Such methodology for determining payment shall be established consistent with section 1902(a)(30)(A).</text>
						</paragraph><paragraph id="H6016925AF6124C5EA9512BF8C10766F4"><enum>(3)</enum><header>Planning grants</header>
 <subparagraph id="HC688D024C2674BAE9966FAAEA4CC829C"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning January 1, 2019, the Secretary may award planning grants to States for purposes of developing a State plan amendment under this section. A planning grant awarded to a State under this paragraph shall remain available until expended.</text>
 </subparagraph><subparagraph id="H5535839B227C42139BE1687EA0878D03"><enum>(B)</enum><header>State contribution</header><text display-inline="yes-display-inline">A State awarded a planning grant shall contribute an amount equal to the State percentage determined under section 1905(b) for each fiscal year for which the grant is awarded.</text>
 </subparagraph></paragraph></subsection><subsection id="HDC2C01F9EE564472A330E53528A7D33A"><enum>(c)</enum><header>Hospital referrals</header><text display-inline="yes-display-inline">A State shall include in the State plan amendment a requirement for any hospital that is a participating provider under the State plan (or a waiver of such plan) to establish procedures for referring any eligible individual who seeks or needs treatment in a hospital emergency department to a health care provider who is qualified (as determined by the State) to provide whole genome sequencing clinical services.</text>
 </subsection><subsection id="H706DB0DD4AC54FC6B222F6FC97D32701"><enum>(d)</enum><header>Reports by States</header><text display-inline="yes-display-inline">Not later than three years after the date on which the State plan amendment under this section is approved, a State shall submit a report to the Administrator of the Centers for Medicare &amp; Medicaid Services and the Administrator of the Health Resources and Services Administration on—</text>
 <paragraph id="H77B966655279490C882A3365EB3F3FD2"><enum>(1)</enum><text>the extent to which whole genomic sequencing clinical services reduce health disparities; and</text> </paragraph><paragraph id="H8641674CF52F47DB87B1D22E571B0AFA"><enum>(2)</enum><text>the extent to which coverage under the State plan (or a waiver of such plan) impedes the use of genetic and genomic testing that may improve clinical outcomes for eligible individuals enrolled in the State plan (or under a waiver of such plan).</text>
 </paragraph></subsection><subsection id="HC7D124930EEB43DEB9A4DC0FF660AECB"><enum>(e)</enum><header>Reports by health care providers</header><text display-inline="yes-display-inline">As a condition for receiving payment for whole genome sequencing clinical services provided to an eligible individual, a health care provider shall report to the State, in accordance with such requirements as the Secretary shall specify, on all applicable measures for determining the quality of such services.</text>
 </subsection><subsection id="HDEBC41A7AEC447E18700AED88510721A"><enum>(f)</enum><header>Definitions</header><text>In this section:</text> <paragraph id="HD2716CED8440499A8FF6542FAC0FA273"><enum>(1)</enum><header>Eligible individual</header><text display-inline="yes-display-inline">The term <term>eligible individual</term> means an individual who—</text>
 <subparagraph id="H9316A9E4A4374F449DEC1A70461105A4"><enum>(A)</enum><text display-inline="yes-display-inline">is eligible for medical assistance under the State plan (or a waiver of such plan);</text> </subparagraph><subparagraph id="HE399D2D8883142D6AFA13BB92F4E7E52"><enum>(B)</enum><text>is under the age of 21 (or, at the option of the State, under the age of 20, 19, or 18 as the State may choose), or in the case of an individual described in section 1902(a)(10)(A)(i)(IX), under the age of 26;</text>
 </subparagraph><subparagraph id="H66C65EA9B2284F76A7DD7E9DAE42D04D"><enum>(C)</enum><text display-inline="yes-display-inline">has been referred or admitted to a pediatric intensive care unit for a chronic or undiagnosed disease;</text>
 </subparagraph><subparagraph id="HBBE4EFB66AA04ACEA389A4CB4F3DE68E"><enum>(D)</enum><text display-inline="yes-display-inline">has been seen by at least one medical specialist for such chronic or undiagnosed disease; and</text> </subparagraph><subparagraph id="H44417F4558B841AEA14EA27C7264DFFA"><enum>(E)</enum><text>is suspected by at least one medical specialist to have a pediatric-onset genetic disease.</text>
 </subparagraph></paragraph><paragraph id="H4746609507C7473C8AA349F12D4D5487"><enum>(2)</enum><header>Whole genome sequencing clinical services</header><text display-inline="yes-display-inline">The term <term>whole genome sequencing clinical services</term>, with respect to an eligible individual—</text> <subparagraph id="HA43BA2E203844EA7BEF3E95DE98F61AB"><enum>(A)</enum><text>means the unbiased sequencing of all deoxyribonucleic acid bases in the genome of such individual and, if for the sole benefit of the individual, a biological parent of such individual for the purpose of determining whether one or more potentially disease-causing genetic variants are present in the genome of such individual or such biological parent; and</text>
 </subparagraph><subparagraph id="HD7796031C0DC488BACF59C2E187A60B5"><enum>(B)</enum><text>includes any analysis, interpretation, and data report derived from such sequencing.</text></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block> </section></legis-body></bill> 

